These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31897485)

  • 1. BET inhibition prevents aberrant RUNX1 and ERG transcription in STAG2 mutant leukaemia cells.
    Antony J; Gimenez G; Taylor T; Khatoon U; Day R; Morison IM; Horsfield JA
    J Mol Cell Biol; 2020 Jun; 12(5):397-399. PubMed ID: 31897485
    [No Abstract]   [Full Text] [Related]  

  • 2. Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.
    Mazumdar C; Shen Y; Xavy S; Zhao F; Reinisch A; Li R; Corces MR; Flynn RA; Buenrostro JD; Chan SM; Thomas D; Koenig JL; Hong WJ; Chang HY; Majeti R
    Cell Stem Cell; 2015 Dec; 17(6):675-688. PubMed ID: 26607380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Cohesin-RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes.
    Ochi Y; Kon A; Sakata T; Nakagawa MM; Nakazawa N; Kakuta M; Kataoka K; Koseki H; Nakayama M; Morishita D; Tsuruyama T; Saiki R; Yoda A; Okuda R; Yoshizato T; Yoshida K; Shiozawa Y; Nannya Y; Kotani S; Kogure Y; Kakiuchi N; Nishimura T; Makishima H; Malcovati L; Yokoyama A; Takeuchi K; Sugihara E; Sato TA; Sanada M; Takaori-Kondo A; Cazzola M; Kengaku M; Miyano S; Shirahige K; Suzuki HI; Ogawa S
    Cancer Discov; 2020 Jun; 10(6):836-853. PubMed ID: 32249213
    [No Abstract]   [Full Text] [Related]  

  • 4. Dysregulation of NIPBL leads to impaired RUNX1 expression and haematopoietic defects.
    Mazzola M; Pezzotta A; Fazio G; Rigamonti A; Bresciani E; Gaudenzi G; Pelleri MC; Saitta C; Ferrari L; Parma M; Fumagalli M; Biondi A; Cazzaniga G; Marozzi A; Pistocchi A
    J Cell Mol Med; 2020 Jun; 24(11):6272-6282. PubMed ID: 32323916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia?
    Osato M; Ito Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):217-28. PubMed ID: 16390318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
    Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
    Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel function of PITH domain-containing 1 as an activator of internal ribosomal entry site to enhance RUNX1 expression and promote megakaryocyte differentiation.
    Lu B; Sun X; Chen Y; Jin Q; Liang Q; Liu S; Li Y; Zhou Y; Li W; Huang Z
    Cell Mol Life Sci; 2015 Feb; 72(4):821-32. PubMed ID: 25134913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular pathogenesis of myelodysplastic syndromes with concurrent mutations in cohesin STAG2 and transcription factor RUNX1].
    Ochi Y
    Rinsho Ketsueki; 2021; 62(5):352-359. PubMed ID: 34108313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia.
    Kodgule R; Goldman JW; Monovich AC; Saari T; Aguilar AR; Hall CN; Rajesh N; Gupta J; Chu SA; Ye L; Gurumurthy A; Iyer A; Brown NA; Chiang MY; Cieslik MP; Ryan RJH
    Blood Cancer Discov; 2023 Jan; 4(1):34-53. PubMed ID: 36350827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group.
    Noort S; Zimmermann M; Reinhardt D; Cuccuini W; Pigazzi M; Smith J; Ries RE; Alonzo TA; Hirsch B; Tomizawa D; Locatelli F; Gruber TA; Raimondi S; Sonneveld E; Cheuk DK; Dworzak M; Stary J; Abrahamsson J; Arad-Cohen N; Czogala M; De Moerloose B; Hasle H; Meshinchi S; van den Heuvel-Eibrink M; Zwaan CM
    Blood; 2018 Oct; 132(15):1584-1592. PubMed ID: 30150206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nonreceptor tyrosine kinase c-Abl phosphorylates Runx1 and regulates Runx1-mediated megakaryocyte maturation.
    Liu H; Cui Y; Wang GF; Dong Q; Yao Y; Li P; Cao C; Liu X
    Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1060-1072. PubMed ID: 29730354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies.
    Wang H; Li W; Guo R; Sun J; Cui J; Wang G; Hoffman AR; Hu JF
    Int J Cancer; 2014 Dec; 135(12):2783-94. PubMed ID: 24752773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.
    Koh CP; Wang CQ; Ng CE; Ito Y; Araki M; Tergaonkar V; Huang G; Osato M
    Leukemia; 2013 Sep; 27(9):1793-802. PubMed ID: 23817177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1: A microRNA hub in normal and malignant hematopoiesis.
    Rossetti S; Sacchi N
    Int J Mol Sci; 2013 Jan; 14(1):1566-88. PubMed ID: 23344057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.
    Ott CJ; Federation AJ; Schwartz LS; Kasar S; Klitgaard JL; Lenci R; Li Q; Lawlor M; Fernandes SM; Souza A; Polaski D; Gadi D; Freedman ML; Brown JR; Bradner JE
    Cancer Cell; 2018 Dec; 34(6):982-995.e7. PubMed ID: 30503705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cohesin and CTCF differentially regulate spatiotemporal runx1 expression during zebrafish development.
    Marsman J; O'Neill AC; Kao BR; Rhodes JM; Meier M; Antony J; Mönnich M; Horsfield JA
    Biochim Biophys Acta; 2014 Jan; 1839(1):50-61. PubMed ID: 24321385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia.
    Xu LS; Francis A; Turkistany S; Shukla D; Wong A; Batista CR; DeKoter RP
    Exp Hematol; 2019 May; 73():50-63.e2. PubMed ID: 30986496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
    Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
    Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLCA2, a novel RUNX1 partner gene in a therapy-related leukemia with t(1;21)(p22;q22).
    Giguère A; Hébert J
    Cancer Genet Cytogenet; 2010 Oct; 202(2):94-100. PubMed ID: 20875871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.